Descripción:

ODM derived from http://clinicaltrials.gov/show/NCT00701766

Link:
http://clinicaltrials.gov/show/NCT00701766
Palabras clave:
  1. 9/12/13 9/12/13 - Martin Dugas
  2. 16/4/14 16/4/14 - Julian Varghese
  3. 16/4/14 16/4/14 - Julian Varghese
  4. 20/9/21 20/9/21 -
Subido en:

16 de abril de 2014

DOI:
Para solicitar uno, por favor iniciar sesión.
Licencia :
Creative Commons BY-NC 3.0 Legacy
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility NCT00701766 Leukemia, Myeloid, Acute

Eligibility

  1. StudyEvent: Eligibility
    1. Eligibility
Einschlusskriterien
Alter mindestens 60 Jahre
Alter über 60 Jahre
Patient with confirmed AML (except for APL) according to the WHO definition who relapsed after or are refractory to prior chemotherapy
Leukozyten-Anzahl
Patient not eligible for intensive treatment options
Life expectancy >= 2 months
ECOG Status <= 2
Signed written informed consent consistent with international conference on harmonisation - good clinical practice (ICH-GCP) and local legislation
Ausschlusskriterien
Patient with acute promyelocytic leukaemia (APL, AML of the French-American-British (FAB) classification subtype M3)
Hypersensitivity to the trial drug or the excipients
Secondary malignancy requiring therapy
Zentralnervensystembeteiligung, Status
Aspartate amino transferase (AST) or alanine amino transferase (ALT) > 2.5 times the upper limit of normal, or AST or ALT > 5 times the upper limit of normal in case of known liver involvement
Bilirubin > 1.5 mg/dl (> 26 mcmol/l, SI unit equivalent)
Kreatinin im Serum
Concomitant intercurrent illness, which would compromise the evaluation of efficacy or safety of the trial drug, e.g. active severe infection, unstable angina pectoris or cardiac arrhythmia
Psychiatric illness or social situation that would limit compliance with trial requirements
Concomitant therapy, which is considered relevant for the evaluation of the efficacy or safety of the trial drug
Chemotherapy (except hydroxyurea) or immunotherapy or treatment with any other investigational drug within the past four weeks prior to treatment with the trial drug
Persistence of toxicities of prior anti-leukaemia therapies which are deemed to be clinically relevant
Patients who are sexually active and unwilling to use a medically acceptable method of contraception during the trial (hormonal contraception, intrauterine device, condom with spermicide, etc.)
Patient unable to comply with the protocol

Similar models

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial